Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MST-312
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
MST-312 (Telomerase Inhibitor IX) is a cell-permeable, reversible small molecule inhibitor of telomerase (IC50 = 0.67 μM). Chemically derived from epigallocatechin gallate (EGCG), the primary catechin in green tea, MST-312 exhibits improved stability and potency compared to its parent compound. It induces telomere shortening, DNA damage response, and apoptosis in various cancer cell lines, including multiple myeloma, breast cancer, and ovarian cancer. Additionally, MST-312 has demonstrated antiviral properties by inhibiting the replication of herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) in epithelial and neuronal cells.
- Other names
- N,N'-1,3-phenylenebis[2,3-dihydroxy-benzamide]N,N′-bis(2,3-dihydroxybenzoyl)-1,3-phenylenediamineTelomerase Inhibitor IX
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on MST-312.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MST-312.